Concord Biotech Limited has informed the Exchange regarding Appointment of M/s Manubhai and Shah LLP as Other of the company w.e.f. April 01, 2026.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech's Board Meeting on May 29, 2026 approved audited standalone and consolidated financial results for FY2026 ending March 31. Revenue from operations stood at Rs 1,05,507.10 lakhs, down from Rs 1,20,008.69 lakhs in FY2025. Profit after tax declined to Rs 26,326.67 lakhs from Rs 37,296.44 lakhs in the prior year, with EPS falling to Rs 25.17 from Rs 35.65. The Board recommended a dividend of Rs 7.55 per equity share for FY2025-26, with record date July 24, 2026. New appointments include M/s Manubhai & Shah LLP as Internal Auditor and M/s Dalwadi & Associates as Cost Auditor for FY2026-27. Mrs. Ekta Gupta was appointed as Additional Independent Director from June 1, 2026 for a 5-year term. Additionally, Celliimune Biotech Private Limited became a wholly-owned subsidiary on April 2, 2026.
The company reported lower revenues and profits year-on-year, which could be a concern for investors. However, the dividend payout and new independent director appointment demonstrate continued commitment to shareholder returns and governance improvements.